Nannini L J, Pendino J C, Corna R A, Mannarino S, Quispe R
Neumonología, Hospital G. Baigorria, Universidad Nacional Rosario, Argentina.
Am J Med. 2000 Feb 15;108(3):193-7. doi: 10.1016/s0002-9343(99)00463-5.
Magnesium sulfate is thought to be an effective bronchodilator when administered intravenously to patients with acute severe asthma, and it can be safely administered via inhalation to patients with stable asthma. Our goal was to determine if isotonic magnesium sulfate could be used as a vehicle for nebulized salbutamol for patients with acute asthma.
We enrolled 35 patients with acute asthma in a randomized, double-blind, controlled trial. After measurement of peak expiratory flow, patients received 2.5 mg salbutamol plus either 3 mL normal saline solution (n = 16) or isotonic magnesium sulfate (n = 19) through a jet nebulizer. Peak flow was reassessed 10 and 20 minutes after treatment.
Peak flow at baseline was similar in the two groups. Ten minutes after baseline, the mean (+/- SD) percentage increase in peak flow was greater in the magnesium sulfate-salbutamol group (61% +/- 45%) than in the normal saline-salbutamol group (31% +/- 28%; difference = 30%; 95% confidence interval [CI] for the difference: 3% to 56%; P = 0.03). At 20 minutes, the percentage increase in peak flow was 57% greater in the magnesium sulfate group (95% CI: 4% to 110%, P = 0.04). There was a significant inverse correlation between baseline peak flow (percent of predicted) and the percentage increase in peak flow at 20 minutes in the magnesium sulfate group (r = -0.82, P <0.0001), but not in the saline group (r = -0.12, P = 0.67).
In patients with acute asthma, isotonic magnesium sulfate, as a vehicle for nebulized salbutamol, increased the peak flow response to treatment in comparison with salbutamol plus normal saline.
静脉注射硫酸镁被认为对急性重症哮喘患者是一种有效的支气管扩张剂，且它可安全地用于稳定期哮喘患者的吸入治疗。我们的目标是确定等渗硫酸镁是否可作为急性哮喘患者雾化沙丁胺醇的载体。
我们将35例急性哮喘患者纳入一项随机、双盲、对照试验。在测量呼气峰值流速后，患者通过喷射雾化器接受2.5毫克沙丁胺醇加3毫升生理盐水溶液（n = 16）或等渗硫酸镁（n = 19）。治疗后10分钟和20分钟重新评估峰值流速。
两组基线时的峰值流速相似。基线后10分钟，硫酸镁-沙丁胺醇组峰值流速的平均（±标准差）增加百分比（61%±45%）高于生理盐水-沙丁胺醇组（31%±28%；差异 = 30%；差异的95%置信区间[CI]：3%至56%；P = 0.03）。在20分钟时，硫酸镁组峰值流速的增加百分比高57%（95%CI：4%至110%，P = 0.04）。在硫酸镁组中，基线峰值流速（预测值的百分比）与20分钟时峰值流速的增加百分比之间存在显著负相关（r = -0.82，P <0.0001），而在生理盐水组中则无相关性（r = -0.12，P = 0.67）。
对于急性哮喘患者，等渗硫酸镁作为雾化沙丁胺醇的载体，与沙丁胺醇加生理盐水相比，增加了治疗后的峰值流速反应。
